First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies.Kyriakos P. Papadopoulos, Glenn S. Kroog, Ding Wang et al.|Journal of Clinical Oncology|2019Cited by 38
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced MelanomaOmid Hamid, Giuseppe Gullo, Karl D. Lewis et al.|Journal of Clinical Oncology|2024Cited by 37